Effects of Daikenchuto on Abdominal Bloating Accompanied by Chronic Constipation: A Prospective, Single-Center Randomized Open Trial  by Yuki, Mika et al.
Current Therapeutic Research 77 (2015) 58–62Contents lists available at ScienceDirectCurrent Therapeutic Researchhttp://d
0011-39
n Add
Medicin
691-000
E-mjournal homepage: www.elsevier.com/locate/cuthreEffects of Daikenchuto on Abdominal Bloating Accompanied by
Chronic Constipation: A Prospective, Single-Center Randomized
Open Trial
Mika Yuki1, Yoshinori Komazawa1,n, Yoshiya Kobayashi1, Maho Kusunoki1,
Yoshiko Takahashi1, Sayaka Nakashima1, Goichi Uno1, Isao Ikuma1, Toshihiro Shizuku1,
Yoshikazu Kinoshita2
1 Department of Internal Medicine, Izumo City General Medical Center, Izumo, Shimane, Japan
2 Second Department of Internal Medicine, Shimane University, School of Medicine, Izumo, Shimane, Japana r t i c l e i n f o
Article history:
Accepted 22 April 2015
Background: Daikenchuto (DKT), a traditional Japanese herbal medicine, is widely used for treatment of
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with chronic constipation.
Objective: To evaluate the efﬁcacy and safety of DKT for the treatment of abdominal bloating.
Methods: After discontinuing as-needed use of laxatives, 10 patients received oral DKT for 14 days (15 g/
d). To evaluate small intestinal bacteria overgrowth (SIBO), a glucose breath test was performed before
and after treatment with DKT. Before beginning the treatment, 4 patients (40%) had a diagnosis of SIBO
based on a positive glucose breath test result. In both the SIBO and non-SIBO groups, bowel movement
frequency and stool form remained unchanged after DKT treatment.
Results: For all patients, median total Gastrointestinal Symptoms Rating Scale score and the median
Gastrointestinal Symptoms Rating Scale indigestion and constipation subscales were signiﬁcantly
decreased, whereas the median visual analog score for decreased abdominal bloating was signiﬁcantly
increased. Improvements of those symptoms were the same in both the SIBO and non-SIBO groups,
indicating that DKT does not have effects on small intestine bacteria. No serious side effects were
reported.
Conclusions: DKT treatment improved quality of life for patients with chronic constipation regardless of
the presence of SIBO and showed no effects on small intestine bacteria. UMIN Clinical Trial Registry
identiﬁer: UMIN000008070.
& 2015. The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The main treatment modalities for patients with chronic con-
stipation include laxatives, antiﬂatulence drugs, enterokinesis-
regulating agents, cholinolytic drugs, and high-molecular-weight
polymer administrations, as well as enemas and other methods.
However, extended use of those treatments may cause abdominal
pain and/or diarrhea, which can lower patient satisfaction. In
patients with chronic constipation, abdominal bloating may have
a serious negative inﬂuence on quality of life (QOL) to a greaterInc. This is an open access article u
wa, Department of Internal
adabun-cho, Izumo, Shimane
.degree than abnormal bowel habits and there is no standard
regimen available for this distressing condition. Daikenchuto
(DKT) (TJ-100), a traditional Japanese herbal medicine, has been
widely used in Japan for treatment of gastrointestinal disorders
such as postoperative ileus and irritable bowel syndrome. Previous
studies have reported that DKT increased the level of calcitonin
gene-related peptide and adrenomedullin, leading to increased
intestinal blood ﬂow in healthy subjects.1 And recent study2
revealed that DKT serves as a novel therapeutic agent for post-
operative ileus characterized by its anti-inﬂammatory potency.
DKT’s anti-inﬂammatory action is partly mediated by activation of
alpha7 nicotinic acetylcholine receptors, which in turn ameliorated
gastrointestinal motility disorder in postoperative ileus in mouse.2
DKT is composed of 3 crude agents in ﬁxed proportions:
Zingiberis rhizoma (processed ginger), Ginseng radix (Panaxnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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the form of extracted granules that are initially prepared by
decocting the 3 crude agents in a 10-fold volume of puriﬁed water
and keeping the mixture at 951C for 1 hour, after which it is
ﬁltered and spray-dried to yield an extract powder. Subsequently,
maltose syrup powder is added at a ratio of 1:8, then mixed and
granulated to produce the ﬁnal product. The current indication of
DKT is for relief of abdominal coldness and pain accompanied by
ﬂatulence.
The purpose of our study was to evaluate the efﬁcacy and safety
of DKT for treatment of abdominal bloating in patients with
chronic constipation.6
7 Total symptom
GSRSPatients and Methods
Study design and subjects
This prospective single-center randomized open trial was
conducted to evaluate the efﬁcacy and safety of DKT for abdominal
bloating accompanied by chronic constipation. The study was
conducted in accordance with the Declaration of Helsinki and
approved by the ethics committee of Izumo-City General Medical
Center, and registered in the UMIN Clinical Trial Registry
(UMIN000008070). Study participants were enrolled from April
2011 to March 2013. Ten patients (3 men and 7 women; mean age
58.4 [19.5] years) with abdominal bloating received oral admin-
istrations (15 g/d 3 times/d before meals) of DKT (Tsumura & Co,
Tokyo, Japan) for 14 consecutive days, during which any as-needed
use of laxatives was discontinued (Table). Participating patients
fulﬁlled the following criteria: abdominal bloating; able to cease
use of laxatives, including on-demand use, during the study
period; and liver function at less than the upper limit of normal
set by our institution, determined within 6 months. Patients with
organic colonic lesions or a history of total gastrectomy or
colectomy were excluded from the study. Functional constipation
patients were excluded, as were patients with organic causes of
constipation such as diabetes mellitus, Parkinson disease, or a
neurologic aliment. Patients who had taken kampo medicines,
antibiotics, Lactobacillus, antacids, prokinetics, calcium polycarbo-
phil, anticholinergics, laxatives, antidepressants, or antianxiety
drugs within 2 weeks were also excluded from our study.
Evaluation of abdominal symptoms
QOL was evaluated at the baseline, then on days 7 and 14 using
the Japanese version of the Gastrointestinal Symptoms Rating
Scale (GSRS) and abdominal bloating and overall treatment effect
were assessed using a visual analog scale (VAS) score (0–100; 0 ¼
none). GSRS and VAS were used in evaluating feelings of full-
ness.3,4 The frequency of bowel movements, stool consistency andTable 1
Characteristics of enrolled patients.
Characteristic Result
Number of patients 10
Age, y
Mean (SD) 58.4 (20.6)
Range 34-85
Gender
Men 3
Women 7
Body mass index
Mean (SD) 23.6 (3.8)
Range 18.731.2form (Bristol Stool Scale),5 and abdominal symptoms were eval-
uated using a face scale with a daily diary.
Glucose breath test (GBT)
To evaluate small intestinal bacteria overgrowth (SIBO), a GBT
was performed before and after administration of DKT using a
Gastrolyzer (Bedfont Scientiﬁc Ltd, Kent, England). Diagnosis of
SIBO was deﬁned by a change in hydrogen concentration of 410
ppm in expired air after being given 100 g glucose.
Statistical analysis
Data for comparisons between groups were analyzed using χ2,
ANOVA, and Wilcoxon’s signed rank tests. Categorical data were
compared using Wilcoxon’s rank sum test; Student t test; or, where
unequal variances occurred, Welch’s test. P values o 0.05 were
considered signiﬁcant. All statistical analyses were performed using
SPSS (version 12.0 for PC, SPSS Japan Inc. Tokyo, Japan).Results
Four patients (40%) were positive for SIBO based on GBT results.
In an analysis of all patients, no changes were observed in
frequency of bowel movements or stool form after DKT treatment.
In contrast, there was a signiﬁcant decrease in median total GSRS
score (Figure 1), and median GSRS indigestion and constipation
subscales (ANOVA P o 0.001), whereas acid reﬂex, diarrhea, and
abdominal pain subscales did not show signiﬁcant changes
(Figure 2). For abdominal bloating, the median VAS score was
notably reduced from 76 to 30 (P ¼ 0.005), whereas the score for
overall treatment effect increased from 13 to 51 (P ¼ 0.005).
Furthermore, the severity of abdominal pain and bloating assessed
by a face scale signiﬁcantly decreased (P ¼ 0.039 and P ¼ 0.008,
respectively) (Figure 3). Improvements in these symptoms were
observed in both the SIBO and non-SIBO groups. In addition, QOL
scores improved (decreased median total GSRS score, median GSRS
constipation subscales, and median VAS score for abdominal
bloating and increased median VAS score for overall treatment
effect) in both groups. In the SIBO group, GBT results showed
similar patterns before and after administration of DKT. DKT did
not affect bowel movement frequency or stool form in all patients
(Figure 4), nor after dividing patients into SIBO and non-SIBO
groups. Furthermore the GBT results showed similar patterns
before and after administration of DKT in the SIBO group and1
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Figure 1. There was a signiﬁcant decrease in median total Gastrointestinal
Symptoms Rating Scale (GSRS) score.
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Figure 2. There were signiﬁcant decreases in indigestion and constipation subscales of the Gastrointestinal Symptoms Rating Scale (GSRS), whereas acid reﬂex, diarrhea, and
abdominal pain subscales did not show signiﬁcant changes.
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any of the patients during the 14-day treatment period.Discussion
The purpose of our study was to evaluate the efﬁcacy of DKT for
abdominal symptoms in patients with chronic constipation.Visual analog
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Figure 3. For abdominal bloating the median visual analog score was notably reduced,
pain and bloating assessed by a face scale signiﬁcantly decreased.Functional constipation has a complex pathophysiology. Prior
clinical studies found that DKT alleviated constipation in patients
with Parkinson disease6 and was also effective for postoperative
ileus.7 In other studies,8,9 DKT stimulated gastrointestinal motility
in healthy subjects and decreased rectal compliance and sensation
in patients with constipation.10
Although good ﬁndings have been reported, the mechanisms
that generate clinical beneﬁts related to DKT remain unidentiﬁed.ue scale
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Figure 4. Daikenchuto did not affect bowel movement frequency or stool form in all patients, nor after dividing into the small intestinal bacteria overgrowth (SIBO) and non-
SIBO groups.
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and abdominal pain in patients with chronic constipation who
required the stimulant sennoside.4 Sennoside is frequently given
for chronic constipation. However, protracted use of laxatives,
including sennoside, increases the frequency of bowel movements
and may impair patient QOL.
We enrolled patients with chronic constipation who were
willing to discontinue the use of laxatives, including on-demand
use, and evaluated the efﬁcacy of DKT therapy without concom-
itant drugs. We found a noteworthy decrease in median total GSRS
score and median GSRS indigestion and constipation subscales,
along with improvements in bloating and abdominal pain symp-
toms. On the other hand, no signiﬁcant changes were observed for
bowel movement frequency or stool form. Furthermore, bloating
was not improved with defecation. Bloating in individuals withGlucose breath test ppm H2
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Figure 5. The glucose breath test results (in parts per million of hydrogen [ppm H2]) sh
intestinal bacteria overgrowth (SIBO) group and non-SIBO groups.chronic constipation can have various causes other than stool
stagnation and may be affected by DKT.
Possible pathogenic factors related to abdominal bloating
include overproduction of abdominal gas, hypersensitivity to
bowel distention, and excessive distention of the colon due to
constipation. According to a past report,11 DKT may directly
stimulate colonic motility and reduce colonic gas volume in
patients after stroke, whereas another suggested that a 5-day
administration of DKT stimulates the small intestine and enhances
ascending colon transit in healthy adults.12 Such effects have also
been reported in dogs and guinea pigs.13
SIBO is a pathologic condition in which abdominal gas is
produced in the upper small intestine, possibly causing unpleasant
abdominal symptoms. As with abdominal bloating, effective treat-
ments for SIBO have yet to be established. A recent study14 foundin SIBO (Case5)
minute
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owed similar patterns before and after administration of daikenchuto in the small
M. Yuki et al. / Current Therapeutic Research 77 (2015) 58–6262that gut microbiome diversity was lacking in a rat model of
inﬂammatory bowel disease, whereas DKT prevented bacterial
translocation by suppression of cytokines and apoptosis in a fast-
stress applied rat model.
In our study there was no increase in bowel movement
frequency despite improvements in bloating and abdominal pain
in both the SIBO and non-SIBO groups. Furthermore, the GBT
results showed similar patterns before and after administration of
DKT in the SIBO group and non-SIBO groups. These results suggest
that a 2-week administration of DKT does not affect bacteria in the
small intestine.
Possible factors that may have led to our ﬁndings are the small
sample size and lack of comparison with a placebo. In addition, the
data were analyzed based on patient symptom scores. Additional
studies with longer follow-up periods and a placebo are required
to evaluate the prolonged inﬂuence of DKT on small intestine
bacteria.Conclusions
DKT administration resulted in improved QOL in patients with
and without SIBO who had chronic constipation. Although the
present 2-week administration protocol seemed to have no effects
on small intestine bacteria, further investigations are necessary to
clarify the feasibility of DKT as treatment for abdominal bloating in
patients with chronic constipation.Conﬂicts of interest
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